Neuroendocrine Tumor Treatment: PET Scan, Ki-67 & PRRT Explained | Dr. Swagat Dash

When is PRRT considered for a patient with a neuroendocrine tumor? What role do PET scans, tumour grade and Ki-67 play in treatment decisions? In this video, Dr. Swagat Dash discusses the diagnostic and treatment approach to neuroendocrine tumors (NETs), including the role of molecular imaging, tumour grading, disease assessment and Peptide Receptor Radionuclide Therapy (PRRT). The video covers: 1. Neuroendocrine tumor diagnosis and staging 2. Role of PET imaging in NETs 3. Tumour grade and Ki-67 4. Somatostatin receptor expression 5. When PRRT may be considered 6. Role of nuclear medicine therapies in NET management Treatment selection is individualised based on the tumour characteristics, disease extent, molecular profile and overall clinical context. 📞 Book your consultation: +91-9953845711 📧 Email: drswagatofficial@gmail.com About Dr. Swagat Dash Dr. Swagat Dash is a Nuclear Theranostic Specialist with 15+ years of experience and HOD & Associate Director – Centre for Nuclear Medicine & Molecular Theranostics, Sarvodaya Hospital and Research Centre, Faridabad, Haryana, India. A Gold Medalist, Dr. Dash has experience in nuclear medicine therapies and the management of prostate cancer, thyroid cancer and neuroendocrine cancers. [Neuroendocrine tumor treatment, neuroendocrine tumor, neuroendocrine cancer, NET treatment, PRRT, PRRT treatment, PRRT for neuroendocrine tumors, Peptide Receptor Radionuclide Therapy, neuroendocrine tumor PET scan, Ki-67 neuroendocrine tumor, nuclear medicine, theranostics, radioligand therapy, targeted radionuclide therapy, PRRT in India, neuroendocrine tumor treatment in India, Best Nuclear Medicine Specialist Delhi NCR] #NeuroendocrineTumor #NeuroendocrineCancer #PRRT #PRRTTreatment #nuclearmedicine #Theranostics #RadioligandTherapy #MolecularImaging #petscan #Ki67 #cancertreatmentindia #precisiononcology #DrSwagatDash